NEURAL CORRELATES OF THE IMPROVEMENT OF MOTOR AND NON-MOTOR SYMPTOMS IN PARKINSON’S DISEASE FOLLOWING A COMBINED DIGITAL AND LEVODOPA THERAPY

Despite the availability of pharmacological treatments, Parkinson’s disease (PD) remains associated with significant unmet clinical needs. We aimed to demonstrate the parallel neural mechanisms underlying the effects of combining standard levodopa treatment with the DopApp digital intervention on motor and non-motor symptoms.
Forty-two PD patients treated with levodopa participated in a prospective, double-blind, randomized, placebo-controlled trial. The 3-week digital treatment consisted of a proprietary daily protocol combining multisensory motor, psychological, and cognitive training. This included fine-motor exercises and rehabilitation-focused modules, along with sensory-depravation tasks and daily walking. Patients were assessed pre- and post-treatment using clinical and psychological scales and resting-state fMRI (rsFC) scans.
DopApp treatment significantly improved the total MDS-UPDRS score compared to placebo-app (inter-group difference of 7.8 points, p=0.0005). Several exploratory endpoints were also statistically significant, including MDS-UPDRS-II,III and Beck Depression Inventory (BDI-II) scores. These effects were associated with parallel modulation of rsFC within the thalamocortical motor and limbic networks. Moreover, increased engagement with sensorimotor and emotion regulation activities correlated with both enhanced clinical effects and rsFC alterations, suggesting a digital dose-response relationship and task-specific neural plasticity.
This study provides preliminary clinical and neurobiological evidence that a targeted, digital therapeutic can augment standard dopaminergic treatment in PD. Dose-response relationships between engagement and outcomes suggest that adaptive, task-specific digital tools may drive circuit-selective plasticity. These findings support the integration of scalable digital interventions into precision drug-digital strategies for neurodegenerative disease treatment, representing an early step toward hybrid approaches that personalize care, enhance efficacy, and extend reach beyond traditional setting.